Straits Times Index
3,338.94 -9.93 (-0.30%) S&P 500
5,283.40 +5.89 (+0.11%) Dow
38,571.03 -115.27 (-0.30%) Nasdaq
16,828.67 +93.67 (+0.56%) Bitcoin USD
68,621.95 -429.95 (-0.62%) CMC Crypto 200
1,440.20 -6.95 (-0.48%)
NuCana plc (NCNA)
After hours:
| Previous close | 3.6100 |
| Open | 3.6700 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 3.6000 - 3.8000 |
| 52-week range | 3.4000 - 23.7500 |
| Volume | |
| Avg. volume | 82,623 |
| Market cap | 8.159M |
| Beta (5Y monthly) | 1.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
NuCana to Present at the Jefferies Global Healthcare Conference
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthcare ConferenceDate: Thursday, June 6, 2024Time: 12:30 PM EDTLocation: New York, NY The presentation will be webcast live and available for replay under “Events & Presentations” in the Investors section of the C
- GlobeNewswire
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Event: TD Cowen’s 5th Annual Oncology Innovation SummitDate: Tuesday, May 28, 2024Time: 8:30 AM EDTLocation: Virtual The presentation will be webcast live and available for replay under “Events & Presentations” in the Inve
- GlobeNewswire
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors Anticipated Cash Runway into Q1 2025 EDINBURGH, United Kingdom, May 16, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first quarter ended March 31, 2024 and provided an update on its broad
